Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Российский университет дружбы народов, Москва
Список исп. литературыСкрыть список 1. Bechdolf A, Wagner M, Harrigan S et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiat 2012; 200 (1): 22–9. 2. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R et al. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiat 2008; 64: 376–84. 3. Borgwardt SJ, McGuire PK, Aston J et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiat 2007; 191 (Suppl. 51): 69–75. 4. Bundesministeriums for Gesundheit. Manahmen des Bundesministeriums for Gesundheit zur Umsetzung nationaler Gesundheitsziele. Berlin: Bundesministerium for Gesundheit 2007. 5. Cannon TD, Cornblatt B, McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull 2007; 33: 661–4. 6. Commonwealth Department of Health and Aged Care. Promotion, prevention and early intervention for mental health – a monograph. Canberra: Commonwealth Department of Health and Aged Care 2000. 7. Cornblatt BA, Lencz T, Smith CW et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiat 2007; 68: 546–57. 8. European Commission. Green Paper – Improving mental health of the population: towards a strategy on mental health for the EU. Brussels: European Commission 2005. 9. Gross G. The «basic» symptoms of schizophrenia. Br J Psychiat 1989; 7: 21–5. 10. Gross G, Huber G, Klosterkotter J et al. Bonner Skala fьr die Beurteilung von Basissymptomen (BSABS – Bonn Scale for the Assessment of Basic Symptoms). Berlin: Springer 1987. 11. Hafner H, Maurer K, Lцffler W et al. The ABC schizophrenia study: a preliminary overview of the results. Soc Psychiat Epid 1998; 33: 380–6. 12. Hafner H, Maurer K, Ruhrmann S et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiat Clin Neurosci 2004; 254: 117–28. 13. Hampel H, Frank R, Broich K et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010; 9: 560–74. 14. Handest P, Parnas J. Clinical characteristics of first-admitted patients with ICD-10 schizotypal disorder. Br J Psychiat 2005; 187 (Suppl. 48): s49–54. 15. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression and neuropathology on the matter of their convergence. Mol Psychiat 2005; 10 (Suppl. 3): 40–68. 16. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recent Prog Med 1989; 80: 646–52. 17. Klosterkotter J. The meaning of basic symptoms for the genesis of the schizophrenic nuclear syndrome. Jpn J Psychiat Neurol 1992; 46: 609–30. 18. Klosterkotter J, Hellmich M, Steinmeyer EM et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiat 2001; 58: 158–64. 19. Klosterkotter J, Ruhrmann S, Schultze-Lutter F et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiat 2005; 4: 161–7. 20. Klosterkotter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S. Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiat 2011; 10: 165–74. 21. Marshall M, Lewis S, Lockwood A et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiat 2005; 62: 975–83. 22. McGlashan T, Walsh B, Woods S. The psychosis-risk syndrome. Handbook for diagnosis and follow-up. NY: Oxford University Press 2010. 23. McGlashan T, Zipursky RB, Perkins D et al. The PRIME North America randomized double-blind clinical trial of olanzapine vs placebo in patients at risk of being prodromally symptomatic for psychosis. Study rationale and design. Schizophr Res 2003; 61: 7–18. 24. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiat 2008; 7: 148–56. 25. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiat 2002; 59: 921–8. 26. Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiat 2002; 159: 863–5. 27. Moller P, Husby R. The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophr Bull 2000; 26: 217–32. 28. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br J Psychiat 2004; 185: 291–7. 29. Morrison AP, French P, Parker S et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007; 33: 682–7. 30. Mrazek PJ, Haggerty RJ. Reducing risks for mental disorders: frontiers for preventive intervention research. Washington: National Academy Press 1994. 31. Nordentoft M, Thorup A, Petersen L et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard. Schizophr Res 2006; 83: 29–40. 32. Pantelis C, Velakoulis D, Wood SJ et al. Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies. Int Rev Psychiat 2007; 19: 371–81. 33. Parnas J, Raballo A, Handest P et al. Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen Prodromal Study. World Psychiat 2011; 10: 200–2044. 34. Parnas J, Jansson L, Sass LA et al. Self-experience in the prodromal phases of schizophrenia. Neurol Psychiat Brain Res 1998; 6: 97–106. 35. Parnas J, Cannon TD, Jacobsen B et al. Lifetime DSM-IIIR diagnostic outcomes in the offspring of schizophrenic mothers. Results from the Copenhagen High-Risk Study. Arch Gen Psychiat 1993; 50: 707–14. 36. Parnas J. From predisposition to psychosis: progression of symptoms in schizophrenia. Acta Psychiat Scand 1999; 99 (Suppl. 395): 20–9. 37. Parnas J. Genetics and psychopathology of spectrum phenotypes. Acta Psychiat Scand 2000; 101: 413–5. 38. Parnas J, Bovet P, Zahavi D. Schizophrenic autism: clinical phenomenology and pathogenetic implications. World Psychiat 2002; 1: 131–6. 39. Parnas J. The self and intentionality in the pre-psychotic stages of schizophrenia. A phenomenological study. In: D.Zahavi (ed). Exploring the self. Philosophical and psychopathological perspectives on self-experience. Amsterdam: John Benjamins 2000; p. 115–47. 40. Parnas J, Handest P, Jansson L et al. Anomalous subjective experience among first-admitted schizophrenia spectrum patients: empirical investigation. Psychopathol 2005; 38: 259–67. 41. Parnas J, Handest P, Saebye D et al. Anomalies of subjective experience in schizophrenia and psychotic bipolar illness. Acta Psychiat Scand 2003; 108: 126–33. 42. Phillips LJ, McGorry PD, Yuen HP et al. Medium-term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007; 96: 25–33. 43. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Aust NZ J Psychiat 2000; 34: s164–9. 44. Pukrop R, Schultze-Lutter F, Ruhrmann S et al. Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. J Clin Exp Neuropsychiat 2006; 28: 1388–407. 45. Raballo A, Saebye D, Parnas J. Looking at the schizophrenia spectrum through the prism of self-disorders: an empirical study. Schizophr Bull 2011; 37: 344–51. 46. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiat 2003; 36 (Suppl. 3): s162–7. 47. Ruhrmann S, Schultze-Lutter F, Maier W et al. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiat 2005; 20: 1–6. 48. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiat 2010; 67: 241–51. 49. Sass LA, Parnas J. Schizophrenia, consciousness and the self. Schizophr Bull 2003; 29: 427–44. 50. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009; 35: 5–8. 51. Schultze-Lutter F, Addington J, Ruhrmann S et al. Schizophrenia Proneness Instrument, Adult version (SPI-A). Rome: Fioriti 2007. 52. Schultze-Lutter F, Klosterkotter J, Picker H et al. Predicting first episode psychosis by basic symptom criteria. Clin Neuropsychiat 2007; 4: 11–22. 53. Schultze-Lutter F, Koch E. Schizophrenia Proneness Instrument. Child & Youth version (SPI-CY). Rome: Fioriti 2010. 54. Schultze-Lutter F, Ruhrmann S, Berning J et al. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 2010; 36: 182–91. 55. Schultze-Lutter F, Ruhrmann S, Klosterkotter J. Can schizophrenia be predicted phenomenologically? In: Johannessen JO, Martindale B, Cullberg J (eds). Evolving psychosis. Different stages, different treatments. London, Routledge 2006; p. 104–23. 56. Schultze-Lutter F, Steinmeyer EM, Ruhrmann S et al. The dimensional structure of self-reported «prodromal» disturbances in schizophrenia. Clin Neuropsychiat 2008; 5: 140–50. 57. Schultze-Lutter F, Ruhrmann S, Klosterkotter J. Early detection of psychosis – establishing a service for persons at risk. Eur Psychiat 2009; 24: 1–10. 58. Seidman LJ, Giuliano AJ, Meyer EC et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiat 2010; 67: 578–88. 59. Simon AE, Dvorsky DN, Boesch J et al. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res 2006; 81: 83–90. 60. The European Network of Schizophrenia Networks for the Study of Gene-Environment Interactions (EU-GEI). Schizophrenia aetiology: do gene-environment interactions hold the key? Schizophr Res 2008; 102: 21–6. 61. Witthaus H, Kaufmann C, Bohner G et al. Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiat Res 2008; 173: 163–9. 62. Woods SW, Addington J, Cadenhead KS et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009; 35: 894–908. 63. Woods SW, Tully EM, Walsh BC et al. Aripiprazole in the treatment of the psychosis prodrome. An open-label pilot study. Br J Psychiat 2007; 191 (Suppl. 51): 96–101. 64. World Health Organization. Prevention of mental disorders: effective interventions and policy options. Geneva: World Health Organization 2004. 65. Yung AR, Phillips LJ, McGorry PD et al. Prediction of psychosis. Br J Psychiat 1998; 172 (Suppl. 33): 14–20. 66. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust NZ J Psychiat 2005; 39: 964–71.